Cite
HARVARD Citation
Liu, J. et al. (2022). Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC‐ESCC2019): A multicenter, phase 2 study. International journal of cancer. 151 (1), pp. 128-137. [Online].